NFNobuhiro Fujiyama

Nobuhiro Fujiyama

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nobuhiro Fujiyama has a total of 101 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Identifying Mild Cognitive Impairment from Routinely Collected Physical, Functional and Psychosocial Measures in Community-Dwelling Older Adults: A Comparative Machine-Learning and Regression Modelling Study in the Northern Japanese ORANGE Registry

    by Ayuto Kodama, Takako Ohnuma, Kana Sasaki, Kaoru Sugawara, Nobuhiro Fujiyama, Youko Umetsu, Tsuyoshi Ono, Hidetaka Ota

    Background: Community health check-ups routinely collect non-cognitive data. Whether these support mild cognitive impairment (MCI) triage, and whether machine learning outperforms regression, is unclear. Methods: Cross-sectional analysis of 2650 community-dwelling adults aged ≥ 65 in Akita, Japan (2018–2025). MCI was defined by the NCGG-FAT (1.5 SD, age/education-adjusted norms). Thirty-four pre-specified non-cognitive predictors were modelled using tree ensembles, penalised regression, other machine-learning families and simple reference scores, with stratified 70/30 splitting, DeLong tests, 100 repeated splits, training-derived thresholds, calibration metrics and decision-curve analysis. Results: MCI prevalence was 28.6%. Random forest discriminated best (ROC AUC 0.722, 95% CI 0.681–0.761; PR-AUC 0.542) and was well calibrated (slope 1.048; intercept −0.024), but its advantage over LASSO regression was marginal (ΔAUC +0.031, p = 0.044) and absent versus gradient boosting (p = 0.059). All multivariable models greatly outperformed the Kihon Checklist (AUC 0.550, p < 0.001). Neither operating point was deployable: at 0.5, sensitivity was 0.269 (166/227 cases missed); at the training-derived Youden threshold (0.321), sensitivity was 0.604, specificity 0.699, and PPV 0.445. Net benefit exceeded assess-all/assess-none between threshold probabilities 0.15–0.60. Conclusions: Routine non-cognitive data support moderate, well-calibrated MCI discrimination, but machine learning added little over regression. This is an exploratory triage aid requiring external validation.


  • Open Access

    Everolimus-Involving Immunosuppression Attenuates Renal Interstitial Fibrosis Through Modulation of Mammalian Target of Rapamycin-Related Signal Transduction

    by Takuro Saito, Mitsuru Saito, Ryohei Yamamoto, Ryuichiro Sagehashi, Yu Aoyama, Mizuki Mori, Chika Kajiwara, Kengo Furihata, Hideaki Kagaya, Hironobu Yagishita, et al.

    Chronic allograft dysfunction, driven by interstitial fibrosis and tubular atrophy, remains a major cause of long-term renal allograft loss. Everolimus (EVR), a mammalian target of rapamycin (mTOR) inhibitor, may reduce fibrosis through antifibrotic effects and calcineurin inhibitor minimization. This study aimed to evaluate the impact of EVR-involving immunosuppression on renal allograft fibrosis and to identify predictors of fibrotic progression. A total of 104 living-donor kidney transplant recipients transplanted between 2011 and 2017 were retrospectively analyzed (EVR, n = 61; non-EVR, n = 43). Interstitial fibrosis was quantified in protocol biopsies using digital image analysis. Phosphorylation of the mTOR-signaling proteins p70 ribosomal S6 kinase and eukaryotic translation initiation factor 4E-binding protein 1 was assessed using a semiquantitative immunoreactive score. Multivariable regression analyses identified independent predictors of fibrotic progression. Cytomegalovirus infection was less frequent in the EVR group, whereas acute rejection, graft function, and graft survival were comparable between groups. At 1-year posttransplantation, interstitial fibrosis was significantly lower in the EVR group. EVR significantly suppressed p-4EBP1 phosphorylation and effectively modulated the mTOR-signaling pathway. Multivariable analysis identified the absence of EVR therapy as an independent predictor of accelerated fibrosis. EVR-involving immunosuppression attenuated renal interstitial fibrosis, likely through suppression of mTOR-signaling.

  • Open Access

    Time-stratified daily walking speed measurement via smartphone and its predictive utility for mild cognitive impairment

    by Nobuhiro Fujiyama, Ayuto Kodama, Marco M. Z. Sharkawi, Kazuo Mishima, Hidetaka Ota

    This study evaluated the utility of a smartphone-based walking-speed application for early mild cognitive impairment (MCI) screening under every day, real-world conditions. Community-dwelling adults aged ≥ 65 years were recruited from dementia prevention activities in Yokote City, Akita Prefecture, (entry period: October 2022-January 2023; assessment period: October 2022-May 2023). A walking-speed app was installed on each participant's personal smartphone, and outdoor, GPS-enabled daily walking speed was continuously recorded. At baseline, we collected clinical and physical measures, including infrared-measured 5-meter usual walking speed (UWS), the National Center for Geriatrics and Gerontology-Functional Assessment Tool (NCGG-FAT), and the Touch Panel-type Dementia Assessment Scale (TDAS). Of 123 enrollees, evaluable walking-speed data were obtained from 115. To reduce noise in the raw dataset, segments meeting predefined criteria for walking distance, walking time, walking speed, steps per unit time, and step length were extracted and defined as unconscious walking speed (UcWS). In time-stratified analyses evaluating its potential as a proxy for UWS, UcWS showed a positive correlation with UWS (maximum r = 0.47). Compared with clinical measures, UcWS was significantly slower in MCI positive participants (median comparison p = 0.018; mean comparison p = 0.011), supporting UWS substitutability. Using walking-duration stratification, we identified a foundational UcWS analytic framework that may serve as a practical proxy for UWS using readily obtainable smartphone-based GPS and accelerometer data. Reduced UcWS was also associated with MCI screening positivity, supporting its potential utility as a scalable real-world digital biomarker for early cognitive decline research.

  • Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study

    by Tokiyoshi Tanegashima, Masaki Shiota, Nobuhiro Fujiyama, Shintaro Narita, Tomonori Habuchi, Genshiro Fukuchi, Dai Takamatsu, Yoshinao Oda, Hideaki Miyake, Masayuki Takahashi, et al.

    Immune checkpoint blockade therapies are widely used for cancer treatment, including advanced renal cell carcinoma (RCC). This study aimed to investigate the impact of zygosity in HLA genes and individual HLA genotypes on the efficacy of an anti-PD-1 Ab, nivolumab, in treating advanced RCC. Patient enrollment was conducted across 23 institutions in Japan from August 19, 2019, to September 30, 2020, with follow-up concluding on March 31, 2021. HLA genotype imputation of HLA-A, B, and C, DQB1, and DRB1 loci was performed. Among 222 patients, the presence of at least one homozygosity of the HLA-II allele significantly improved the best objective response (hazard ratio, 0.34; 95% confidence interval, 0.21–0.96; p = 0.042). The HLA evolutionary divergence (HED) of the HLA-A and HLA-B loci was higher than the HLA-C (p < 0.0001 and p < 0.0001, respectively), with high HED of the HLA-B locus correlating to clinical benefits in nivolumab treatment (hazard ratio, 0.44; 95% confidence interval, 0.21–0.90; p = 0.024) and improving cancer-specific survival compared with the low group (p = 0.0202). Additionally, high HED of the HLA-B locus was correlated with the number of infiltrated CD8+ cells in the tumor microenvironment (correlation coefficient, 0.4042). These findings indicate that the diversity of the HLA-B locus plays a significant role in the anti-tumor effect of nivolumab treatment in advanced RCC, potentially offering insights for improved risk stratification in nivolumab treatment and leading to better medical management of advanced RCC.


  • Open Access

    Correction to: Immunological risk and complement genetic evaluations in early onset de novo thrombotic microangiopathy after living donor kidney transplantation: A Japanese multicenter registry

    by Nobuhiro Fujiyama, Masayuki Tasaki, Hiroshi Harada, Koichi Tsutahara, Akihiko Matsumoto, Yuji Kamijo, Mariko Toyoda, Daiki Iwami, Masashi Inui, Hiroki Shirakawa, et al.

  • Open Access

    Automatic Classification of Colored Pills in One Does Package

    by Shuei Tatsumi, Min Zou, Katsuya Sasaki, Hideaki Kagaya, Nobuhiro Fujiyama, Yoichi Kageyama

    Automatic Classification of Colored Pills in One Does Package

  • Immunological risk and complement genetic evaluations in early onset de novo thrombotic microangiopathy after living donor kidney transplantation: A Japanese multicenter registry

    by Nobuhiro Fujiyama, Masayuki Tasaki, Hiroshi Harada, Koichi Tsutahara, Akihiko Matsumoto, Yuji Kamijo, Mariko Toyoda, Daiki Iwami, Masashi Inui, Hiroki Shirakawa, et al.

    Background Thrombotic microangiopathy (TMA) after kidney transplantation (KTx), particularly early onset de novo (dn) TMA, requires immediate interventions to prevent irreversible organ damage. This multicenter study was performed to investigate the allogeneic clinical factors and complement genetic background of dnTMA after KTx. Methods Perioperative dnTMA after KTx within 1 week after KTx were diagnosed based on pathological or/and hematological criteria at each center, and their immunological backgrounds were researched. Twelve aHUS-related gene variants were examined in dnTMA cases. Results Seventeen recipients (15 donors) were enrolled, and all dnTMA cases were onset within 72-h of KTx, and 16 of 17 cases were ABO incompatible. The implementation rate of pre-transplant plasmaphereses therapies were low, including cases with high titers of anti-A/anti-B antibodies. Examination of aHUS-related gene variants revealed some deletions and variants with minor allele frequency (MAF) in Japan or East Asian genome databases in genes encoding alternative pathways and complement regulatory factors. These variants was positive in 8 cases, 6 of which were positive in both recipient and donor, but only in one graft loss case. Conclusions Although some immunological risks were found for dnTMA after KTx, only a few cases developed into TMA. The characteristic variations revealed in the present study may be novel candidates related to dnTMA in Japanese or Asian patients, but not pathogenic variants of aHUS. Future studies on genetic and antigenic factors are needed to identify factors contributing to dnTMA after KTx.

  • Clinical implication of tertially lymphoid tissue in the renal graft

    by M. Saito, Y.H. Lee, Y. Sato, N. Fujiyama, S. Narita, S. Satoh, M. Yanagita, T. Habuchi

  • Clinical implications of pharmacokinetics of sunitinib malate and N-desethyl-sunitinib plasma concentrations for treatment outcome in metastatic renal cell carcinoma patients

    by K. Numakura, N. Fujiyama, M. Takahashi, R. Igarashi, T. Nara, S. Chiba, S. Kanda, M. Saito, S. Narita, T. Inoue, et al.

  • Open Access

    Down-Regulation of Hepatic Transporters for BSP in Rats with Indomethacin-Induced Intestinal Injury

    by Nobuhiro Fujiyama, Yoshihisa Shitara, Kousei Ito, Yasuhiro Masubuchi, Toshiharu Horie

    Previous reports have demonstrated that an intestinal injury causes hypofunctions of the liver associated with down-regulations of cytochrome P450, but an influence on hepatic transporters remains unclear. Here, we tested hepatic transporter functions in a rat model of bowel injury using indomethacin (IDM). After administration of IDM (8.5 mg/kg, i.p., 3 d), the rats suffered the intestinal impairment indicated by a reduction of alkaline phosphatase activity in mucosa. In vivo pharmacokinetic experiments of bromosulfophthalein (BSP) showed that there was a reduction in its plasma elimination rate and cumulative biliary excretion in IDM-treated rats and systemic and biliary clearances reduced to nearly 50% of the control group. Protein expressions in plasma membrane and mRNA levels of organic anion transporting polypeptide 1b2 (Oatp1b2) and multidrug resistance-associated protein 2 (Mrp2), which play hepatic BSP uptake and biliary excretion, respectively, in the liver were significantly reduced following the IDM treatment. In portal plasma, the levels of proinflammatory cytokines were unchanged, while the level of nitric oxide metabolites (NO2−+NO3−) increased to 6.5-fold that of the control. The time-course on IDM treatment indicated that, firstly, intestinal injury was induced, the NO level increased, and the hepatic Oatp1b2 and Mrp2 expression began to fall followed by an increase in plasma ALT. In conclusion, IDM-induced injury to the small intestine causes the hypofunction of hepatic Oatp1b2 and Mrp2 independently on the hepatic impairment, and NO arising from bowel injury may be one of key factors for it through the remote effect.